XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Brokerages

Posted by George Bondi on Jul 24th, 2026

Shares of XOMA Royalty Corporation (NASDAQ:XOMA – Get Free Report) have been assigned an average rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $53.75.

XOMA has been the topic of a number of recent analyst reports. Benchmark downgraded shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Weiss Ratings upgraded shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. HC Wainwright cut shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price on the stock. in a report on Thursday, April 30th. Finally, Lucid Cap Mkts downgraded shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th.

View Our Latest Stock Analysis on XOMA Royalty

Institutional Trading of XOMA Royalty

Several large investors have recently modified their holdings of the company. State of Alaska Department of Revenue purchased a new stake in XOMA Royalty during the fourth quarter valued at $27,000. Russell Investments Group Ltd. boosted its position in XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 756 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. boosted its position in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of XOMA Royalty during the 2nd quarter valued at about $116,000. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Stock Performance

Shares of NASDAQ:XOMA opened at $40.17 on Friday. The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59. XOMA Royalty has a 1 year low of $22.29 and a 1 year high of $45.22. The company has a market cap of $503.77 million, a P/E ratio of 25.59 and a beta of 0.86. The stock’s fifty day moving average price is $41.86 and its 200-day moving average price is $34.61.

XOMA Royalty (NASDAQ:XOMA – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The business had revenue of $12.32 million during the quarter, compared to the consensus estimate of $13.91 million. Sell-side analysts expect that XOMA Royalty will post 0.9 earnings per share for the current year.

About XOMA Royalty

(Get Free Report)

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.